DE69915310D1 - Methoden zur behandlung der salzabhängigen hypertonie - Google Patents

Methoden zur behandlung der salzabhängigen hypertonie

Info

Publication number
DE69915310D1
DE69915310D1 DE69915310T DE69915310T DE69915310D1 DE 69915310 D1 DE69915310 D1 DE 69915310D1 DE 69915310 T DE69915310 T DE 69915310T DE 69915310 T DE69915310 T DE 69915310T DE 69915310 D1 DE69915310 D1 DE 69915310D1
Authority
DE
Germany
Prior art keywords
methods
related hypertension
treating salt
compositions
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69915310T
Other languages
English (en)
Other versions
DE69915310T2 (de
Inventor
F Schreiner
J Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Scios LLC
Original Assignee
Scios LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios LLC filed Critical Scios LLC
Application granted granted Critical
Publication of DE69915310D1 publication Critical patent/DE69915310D1/de
Publication of DE69915310T2 publication Critical patent/DE69915310T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69915310T 1998-09-09 1999-09-09 Methoden zur behandlung der salzabhängigen hypertonie Expired - Fee Related DE69915310T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US9969498P 1998-09-09 1998-09-09
US99694P 1998-09-09
US12640699P 1999-03-26 1999-03-26
US126406P 1999-03-26
US12661599P 1999-03-27 1999-03-27
US126615P 1999-03-27
PCT/US1999/020481 WO2000013703A2 (en) 1998-09-09 1999-09-09 Methods of treating hypertension and compositions for use therein

Publications (2)

Publication Number Publication Date
DE69915310D1 true DE69915310D1 (de) 2004-04-08
DE69915310T2 DE69915310T2 (de) 2005-03-10

Family

ID=27378887

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69915310T Expired - Fee Related DE69915310T2 (de) 1998-09-09 1999-09-09 Methoden zur behandlung der salzabhängigen hypertonie
DE69912815T Expired - Fee Related DE69912815T2 (de) 1998-09-09 1999-09-09 Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69912815T Expired - Fee Related DE69912815T2 (de) 1998-09-09 1999-09-09 Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien

Country Status (13)

Country Link
US (3) US6352975B1 (de)
EP (2) EP1109571B1 (de)
JP (2) JP2002532382A (de)
AT (2) ATE260675T1 (de)
AU (2) AU6028599A (de)
BR (2) BR9913564A (de)
CA (2) CA2340320C (de)
DE (2) DE69915310T2 (de)
DK (2) DK1109571T3 (de)
ES (2) ES2216630T3 (de)
IL (2) IL141686A0 (de)
PT (2) PT1112083E (de)
WO (2) WO2000013703A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1109571B1 (de) * 1998-09-09 2004-03-03 Scios Inc. Methoden zur behandlung der salzabhängigen hypertonie
US6783954B2 (en) * 1999-03-05 2004-08-31 Compugen Ltd. VEGF nucleic acid and amino acid sequences
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
AU782158B2 (en) * 1999-11-02 2005-07-07 Genentech Inc. Modulation of eNOS activity and therapeutic uses thereof
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
EP1414964B1 (de) 2001-08-01 2010-03-24 University Of Bristol Isoform des vegfs
WO2003015605A2 (en) * 2001-08-20 2003-02-27 University Of Virginia Patent Foundation Use of s-nitrosothiol signaling to treat disordered control of breathing
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US7795213B2 (en) 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US20030171556A1 (en) * 2001-12-13 2003-09-11 Chi-Bom Chae Beta-amyloid binding factors and inhibitors thereof
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
JP2006068401A (ja) * 2004-09-03 2006-03-16 Kyushu Institute Of Technology 人工血管
WO2006110813A2 (en) * 2005-04-12 2006-10-19 Intradigm Corporation Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
JP5158779B2 (ja) * 2005-08-31 2013-03-06 国立大学法人 香川大学 Ｄ−アロースを有効成分とする血圧上昇抑制剤
KR101761424B1 (ko) 2008-12-04 2017-07-26 큐알엔에이, 인크. Ｖｅｇｆ에 대한 천연 안티센스 전사체의 억제에 의해 맥관 내피 성장 인자(ｖｅｇｆ) 관련된 질환의 치료
GB0921525D0 (en) * 2009-12-08 2010-01-27 Isis Innovation Product and method
US11229682B2 (en) 2017-03-30 2022-01-25 Wake Forest University Health Sciences Methods of treatment for kidney disease
CN113418940B (zh) * 2021-06-24 2023-03-14 电子科技大学 一种基于x射线示踪颗粒的检测方法及检测装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456550A (en) 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
ATE152626T1 (de) 1989-03-24 1997-05-15 Univ California Endothelialer zellwachsfaktor, isolierung und expression
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5219739A (en) 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5240714A (en) * 1989-08-29 1993-08-31 Rof Jose M S Non-digoxin-like Na+, K+ -ATPase inhibitory factor
US5318957A (en) * 1992-09-02 1994-06-07 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating angiogenesis
JP2001503755A (ja) * 1996-11-01 2001-03-21 ユーロジーン・リミテッド Ｎｏまたはプロスタサイクリン産生を刺激する薬剤の治療的使用およびデリバリー装置
US6485942B1 (en) * 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
EP1109571B1 (de) * 1998-09-09 2004-03-03 Scios Inc. Methoden zur behandlung der salzabhängigen hypertonie

Also Published As

Publication number Publication date
BR9913533A (pt) 2001-06-05
IL141686A0 (en) 2002-03-10
DK1112083T3 (da) 2004-03-08
JP2002532382A (ja) 2002-10-02
CA2340320A1 (en) 2000-03-16
EP1109571B1 (de) 2004-03-03
IL141687A0 (en) 2002-03-10
WO2000013703A3 (en) 2000-07-06
AU6028599A (en) 2000-03-27
WO2000013702A9 (en) 2000-10-19
DE69915310T2 (de) 2005-03-10
EP1112083A2 (de) 2001-07-04
PT1109571E (pt) 2004-05-31
DE69912815T2 (de) 2004-10-21
US20020193288A1 (en) 2002-12-19
US6352975B1 (en) 2002-03-05
WO2000013703A9 (en) 2000-06-02
ATE260675T1 (de) 2004-03-15
ES2216630T3 (es) 2004-10-16
US20040224885A1 (en) 2004-11-11
DE69912815D1 (de) 2003-12-18
AU5910599A (en) 2000-03-27
PT1112083E (pt) 2004-03-31
CA2340728A1 (en) 2000-03-16
DK1109571T3 (da) 2004-06-21
CA2340320C (en) 2006-11-14
CA2340728C (en) 2007-11-27
EP1112083B1 (de) 2003-11-12
WO2000013702A3 (en) 2000-09-08
WO2000013703A2 (en) 2000-03-16
JP2002524421A (ja) 2002-08-06
ATE253934T1 (de) 2003-11-15
WO2000013702A2 (en) 2000-03-16
ES2211165T3 (es) 2004-07-01
EP1109571A2 (de) 2001-06-27
BR9913564A (pt) 2001-05-22

Similar Documents

Publication Publication Date Title
DE69915310D1 (de) Methoden zur behandlung der salzabhängigen hypertonie
BR9707819A (pt) Imunogenos peptidicos
DE69935345D1 (de) Methoden und zusammensetzungen zur prävention und behandlung der anämie
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
MX9702170A (es) Uso de inhibidores de la aromatasa para la produccion de un agente farmaceutico para el tratamiento de una deficiencia de androgeno relativa en los hombres.
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
DK0967987T3 (da) Sammensætning til behandling af tumorer indeholdende hajbruskekstrakter og anitneoplastiske stoffer
DE69921130D1 (de) Verfahren und stoffe zur behandlung des prostatakarzinomes
ATE297198T1 (de) Zusammensetzungen und verfahren zur verbesserung der integrität von angegriffenen körperpassagewegen und höhlen
TR199901703T2 (xx) Siklooksijenaz-2 inhibit�rlerini anti-anjiyojenik ajanlar olarak kullanma y�ntemi.
DK0885005T3 (da) Anvendelse af dehydroepiandrosteron og aromatasehæmmere til fremstilling af et lægemiddel til behandling af en relativ og absolut androgenmangel hos mænd
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
DK1189627T3 (da) Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden
DE60230133D1 (de) Toluolsulfonamid enthaltende antitumorale zusammensetzung und anwendungsverfahren dafür
ATE476987T1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
DE50110552D1 (de) Verfahren zur behandlung von instabiler angina pectoris
ATE405577T1 (de) Lactam dipeptid und dessen verwendung zur inhibierung der beta-amyloid peptid frisetzung
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
ATE332970T1 (de) Verfahren und zusammensetzungen zur hemmung von neoplastischem zellwachstums
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
EP1447089A3 (de) Methoden zur Behandlung von Hypertonie und Zusammensetzungen dafür
DE59904564D1 (de) Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8327 Change in the person/name/address of the patent owner

Owner name: SCIOS INC., FREMONT, CALIF., US

Owner name: UNIVERSITY OF WASHINGTON, SEATTLE, WASH., US

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee